Rodman & Renshaw Initiates Coverage On Eledon Pharmaceuticals with Buy Rating, Announces Price Target of $12

Benzinga Newsdesk www.benzinga.com Neutral 70.5%

Neg 0% Neu 70.5% Pos 0%

Rodman & Renshaw analyst Seema Sheoran initiates coverage on Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy rating and announces Price Target of $12.